FOLH1 and neoplasm: A recent study [61] has shown that an increase in the calculated total tumor volume on the post-treatment SPECT/CT (1st and 2nd cycles) predicts a short PFS and may play a future role as an imaging response biomarker, identifying when to discontinue or intensify [177Lu]Lu-PSMA-617 therapy.